NASDAQ · SRZNW
Surrozen, Inc.
Healthcare · Biotechnology
$0.00
Down-$0.00 (-60.53%)
Updated Oct 10, 2026, 2:48 PM
SID Score
2.7/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 197.15K
- P/E ratio
- -12.03
- Dividend yield
- 0.00%
- 52-week range
- $0.00 – $0.05
- Volume
- 26.47K
- Avg. volume
- 23.48K
Price performance · SRZNW
SRZNW price history
1M range · 0 trading sessions · Daily adjusted prices
SRZNW does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
Latest SRZNW news
The latest Smart Investors Daily articles mentioning SRZNW.
Stock researchCompany · Overview
Company
Market Activity
Research & News
SRZNW research
Overview
Company profile and research snapshot.
Company profile
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- —
- Implied upside
- —
- Analysts
- —
News briefing
No generated briefing is available yet.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
